Navigation Links
Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution
Date:2/18/2009

TEMPO™ for Grant Management assists medical affairs departments in deploying comprehensive investigator-initiated research grant management program

Morrisville, N.C. (PRWEB) February 18, 2009 -- Clinipace, a growing clinical research solutions company, today announced that it has been selected by two pharmaceutical firms to deploy its TEMPO™ for Grant Management solution.

Life science firms are highly cognizant of the multiple pressures to be transparent and compliant in their funding of investigator initiated research (IIR), and are turning to Clinipace in increasing numbers to help them better manage this process. Funding this research is a strategic investment, and maximizing return is critical whether in the form of publications, useful data or stronger community relationships.

Funding investigator-initiated research, in the form of grants, has become an important part of the overall clinical development program, for drugs and devices. This research furthers scientific understanding of real-world clinical profile and product utilization, identifies new indications, and augments the medical literature. As a result, medical affairs departments in many life science companies have established centralized IIR grant management functions and processes.

"Clinipace offers the only software management system that enables life science firms to centralize the application and evaluation process across the portfolio, while simultaneously empowering investigators with the tools and know-how to support individual research projects, all within one software platform. This ensures visibility and success for all stakeholders," said Jeff Williams, Chief Executive Officer at Clinipace.

About Clinipace
Clinipace is an experienced clinical research solutions company providing on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver services such as EDC, ePRO, grant management, data management, monitoring, site management, and biostatistics at a 30% - 50% savings compared to similar service providers.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb2103804.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
2. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
3. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
4. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
5. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
6. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
7. Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
8. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
9. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
10. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
11. Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert ... Core benefits and advantages built into the home office sit stand solution are ... feel. Ability to gain the benefits embedded in the TaskMate Go are available ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, vice ... appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new ... 10. Dr. Bell comes to Liberty from the Ohio University Heritage College of ...
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning ... Gran Fondo of Marin. For the second year in a row, cyclists will ... , “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
Breaking Medicine Technology: